AVROBIO, Inc.: AVROBIO Reports Favorable Data on Use of Comb

AVROBIO, Inc.: AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO leading industry in combining use of two safety assays to evaluate genotoxicity risk prior to moving into clinical trials New safety assay uses machine learning algorithms and transcriptional

Related Keywords

Germany , Boston , Massachusetts , United States , Hannover , Niedersachsen , Cambridge , Cambridgeshire , United Kingdom , Edinburgh , City Of , Scotland , Michael Rothe , Axel Schambach , Geoff Mackay , Christopherf Brinzey , Institute Of Experimental Hematology , Linkedin , Twitter , Hannover Medical School , Harvard Medical School , Nasdaq , Exchange Commission , Division Of Hematology Oncology , European Society Of Gene Cell Therapy , Avrobio Inc , Annual Congress , European Society , Gene Cell Therapy , Professor Axel Schambach , Experimental Hematology , Professor Schambach , Boston Children , Private Securities Litigation Reform Act , Quarterly Report , Bridge Communications , Avrobio , Reports , Favorable , Data , Combined , Estate , Itro , Fell , Ased , Essays , Identify , Potential , Genotoxicity , Risk , Integrating , Sectors , During , Reclinical , Development ,